Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered non-small cell lung cancer and thyroid cancer patients who may be suitable for LOXO-292, Lilly's RET inhibitor CARLSBAD, Calif., Sept. 9... Diagnostics, Biopharmaceuticals, Oncology, Licensing Thermo Fisher Scientific, Eli Lilly, Oncomine Dx Target Test, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsThe adherence to lung dose constraints such as V20 as well as close treatment monitoring are a prerequisite for the management of pneumonitis during maintenance therapy with durvalumab.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
This study aimed to detect the levels of cytokeratin 7 (CK7) and thyroid transcription factor -1(TTF-1) in serum of patients with non-small cell lung cancer (NSCLC) complicated with superior vena cava syndrome (SVCS), and to explore their prognosis and relationship and correlation with pathological characteristics. METHODS: 68 patients with non-small cell lung cancer (NSCLC) complicated with SVCS treated in Shaoxing Second Hospital from July 2014 to May 2018 were selected as the experimental group, 60 normal healthy persons as the control group, and 60 patients with lung cancer as the lung cancer group. The levels of C...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Conclusions: In this study we confirmed that ICI drugs can occasionally develop clearly defined autoimmune systemic diseases besides pulmonary toxicity. While discontinuation of therapy and/or treatment can result in resolution of irAEs, long-term sequelae and death have been reported. More studies are needed in order to develop more precise treatments for immunotherapy-related adverse events.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Yicheng Ni Cancer remains a major cause of death globally. Given its relapsing and fatal features, curing cancer seems to be something hardly possible for the majority of patients. In view of the development in cancer therapies, this article summarizes currently available cancer therapeutics and cure potential by cancer type and stage at diagnosis, based on literature and database reviews. Currently common cancer therapeutics include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, treatment with curative intent by these methods are mainly eligible for patients with localized diseas...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionsLOXO-292 had marked antitumor activity in RET-altered thyroid cancer and was well tolerated. These data will form the basis of an FDA new drug application in late 2019.Clinical trial identificationNCT03157128.Legal entity responsible for the studyLoxo Oncology.FundingLoxo Oncology.DisclosureL.J. Wirth: Advisory / Consultancy: Eisai; Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Loxo; Advisory / Consultancy: Merck. E. Sherman: Advisory / Consultancy: Loxo Oncology; Advisory / Consultancy: COTA consulting; Advisory / Consultancy: Novartis; Advisory / Consultan...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsTPX-0046 is a novel next generation RET/SRC inhibitor with favorable pharmaceutical properties and possesses potent in vitro and in vivo activity against diverse RET alterations, including the SFM G810R. The novel macrocyclic structure may provide opportunities to overcome treatment resistance from current RET inhibitors. TPX-0046 is currently in IND-enabling studies.Legal entity responsible for the studyTurning Point Therapeutics, Inc.FundingTurning Point Therapeutics, Inc.DisclosureE. Rogers: Shareholder / Stockholder / Stock options, Full / Part-time employment: Turning Point Therapeutics, Inc. D. Zhai: Share...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThyroid alterations are frequently associated with anti PD-1 treatment in cancer patients. Regular thyroid assessment should be performed, particularly in the first months of treatment and in patients with a pre-existing thyroid disease.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
Conclusion :18F-FDG PET/CT metabolic parameters combined with clinicopathological data demonstrated moderate diagnostic efficacy in predicting EGFR mutation status and were associated with prognosis in mutant and wild-type EGFR non-small-cell lung cancer, thus providing a reference for individualized targeted molecular therapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: TTF-1 expression in NSCLC might correlate with irTD and anti-PD-1 treatment efficacy. PMID: 31285885 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
ConclusionsANKRD26-RET is a novel rearrangement of the RET gene, associated with RET expression in thyroid tissue. The result is a fusion of the RET tyrosine kinase to prominent protein-protein interaction motifs. Further studies are required to investigate the influence of different RET rearrangements on metastasis and disease-free survival in PTC.
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Thyroid | Thyroid Cancer